68Ga-DOTA-RGD2正电子发射断层扫描/计算机断层扫描在放射性碘难治性甲状腺癌中的应用:与18F-FDG正电子发射断层扫描/计算机断层扫描诊断准确性的前瞻性比较及潜在诊疗一体化评估
前瞻性纳入44例放射性碘难治性分化型甲状腺癌且治疗后131I扫描阴性患者,比较68Ga-DOTA-RGD2 PET/CT与18F-FDG PET/CT诊断准确性。68Ga-DOTA-RGD2 PET/CT灵敏度82.3%、特异度100%、准确率86.4%;18F-FDG PET/CT分别为82.3%、50%、75%。68Ga-DOTA-RGD2 PET/CT灵敏度相似但特异度和准确率更高。
要点
- 68Ga-DOTA-RGD2 PET/CT与18F-FDG PET/CT灵敏度均为82.3%,但特异度100% vs 50%、准确率86.4% vs 75%。
- 最常见病灶为淋巴结转移(82.9%),其次为甲状腺床病灶(10.5%)。
- 68Ga-DOTA-RGD2 PET/CT阳性患者中82.1%病灶摄取高于肝脏(IV级和V级)。
核心结论
- 在放射性碘难治性分化型甲状腺癌患者中,68Ga-DOTA-RGD2 PET/CT检测病灶的灵敏度与18F-FDG PET/CT相似,但特异度和总体准确率更高。
研究设计与样本
- 前瞻性纳入44例放射性碘难治性分化型甲状腺癌且治疗后131I扫描阴性的患者。
- 在左甲状腺素撤药(促甲状腺激素刺激状态)下检测血清甲状腺球蛋白和抗甲状腺球蛋白,并在1周内完成18F-FDG PET/CT和68Ga-DOTA-RGD2 PET/CT检查。
- 随访采用组织病理学/血清甲状腺球蛋白/抗甲状腺球蛋白/常规影像。
主要发现
- 68Ga-DOTA-RGD2 PET/CT共检出123个病灶,总体灵敏度82.3%、特异度100%、准确率86.4%。
- 18F-FDG PET/CT共检出144个病灶,总体灵敏度82.3%、特异度50%、准确率75%。
- 最常见疾病部位为淋巴结转移(82.9%),其次为甲状腺床病灶(10.5%)。
- 68Ga-DOTA-RGD2 PET/CT阳性患者中82.1%显示病灶放射性示踪剂摄取高于肝脏(IV级和V级)。
临床怎么用
- 作者认为,这种血管生成显像 modality 的新应用可能在放射性碘难治性分化型甲状腺癌中有用,尤其是在18F-FDG PET/CT阴性/可疑的患者中。
- 作者认为,由于68Ga-DOTA-RGD2 PET/CT阳性患者中多数(82.1%)显示放射性示踪剂亲和力处于较高端(IV级和V级),新型177Lu为基础的诊疗一体化可能成为这些患者的潜在治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Radioiodine therapy (131I) forms a principal cornerstone in the management of differentiated thyroid cancer. Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) presents a challenge in detection of structural disease in patients with evidence of biochemical disease and in treatment of the disease using alternate therapies. The present study was conducted to compare the diagnostic accuracy (in terms of sensitivity and specificity) of 68Ga-DOTA-RGD2 positron emission tomography (PET)/computed tomography (CT) as a neoangiogenesis imaging modality with 18F-FDG PET/CT, the current standard in diagnostic algorithm of RAIR-DTC, and to evaluate the radiotracer avidity on 68Ga-DOTA-RGD2 PET/CT for potential theranostics. Methods: Forty-four RAIR-DTC patients with negative post-therapy 131I scan were prospectively enrolled. Serum thyroglobulin (sTg) and anti-thyroglobulin (ATg) measurements were performed with levothyroxine withdrawal (thyrotropin-stimulated state), and 18F-FDG PET/CT and 68Ga-DOTA-RGD2 PET/CT studies were performed within 1 week of each other. Follow-up was performed with histopathology/sTg/ATg/conventional imaging. The findings of 18F-FDG PET/CT and 68Ga-DOTA-RGD2 PET/CT were compared with the reference standard to obtain sensitivity, specificity, and overall accuracy. Degree of radiotracer uptake on 68Ga-DOTA-RGD2 PET/CT was described as tumor to background (T/B) and tumor to liver (T/L) ratios of standardized uptake value. Results:68Ga-DOTA-RGD2 PET/CT detected a total of 123 lesions, with an overall sensitivity, specificity, and accuracy of 82.3%, 100%, and 86.4%, respectively. 18F-FDG PET/CT detected a total of 144 lesions, with an overall sensitivity, specificity, and accuracy of 82.3%, 50%, and 75%, respectively. Most commonly identified disease sites were nodal metastases (82.9%), followed by thyroid bed lesions (10.5%). 82.1% of patients positive on 68Ga-DOTA-RGD2 PET/CT showed lesional radiotracer uptake higher than the liver (grade IV and grade V). Conclusions:68Ga-DOTA-RGD2 PET/CT showed a similar sensitivity to, but higher specificity and overall accuracy than 18F-FDG PET/CT in detection of lesions in RAIR-DTC patients. This novel application of the angiogenesis imaging modality can prove useful in RAIR-DTC, especially in patients with negative/suspicious 18F-FDG PET/CT. Furthermore, since the majority of patients (82.1%) positive on 68Ga-DOTA-RGD2 PET/CT showed radiotracer avidity toward the higher end of the spectrum (grade IV and grade V), novel 177Lu-based theranostics can be a potential treatment for these patients.
引用
- Parihar AS, Mittal BR, Kumar R, et al. 68Ga-DOTA-RGD2 Positron Emission Tomography/Computed Tomography in Radioiodine Refractory Thyroid Cancer: Prospective Comparison of Diagnostic Accuracy with 18F-FDG Positron Emission Tomography/Computed Tomography and Evaluation Toward Potential Theranostics. Thyroid. 2020. PMID: 31870227. doi:10.1089/thy.2019.0450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。